Amplifier Therapeutics

Amplifier Therapeutics is a biopharmaceutical startup striving to harness the broad therapeutic applications of AMPK activation. The company, which operates as part of Cambrian Bio PipeCo, was founded in 2001 and is dedicated to developing AMP-activated protein kinase (AMPK) activator compounds for the treatment of various age-related diseases spanning metabolic conditions, cardiovascular diseases, kidney diseases, and cancer. As a Distributed Development Company (DisCo), Cambrian is concurrently advancing multiple scientific breakthroughs, each aimed at addressing a biological driver of aging. The company's strategy entails the development of interventions to target specific diseases initially, followed by the deployment of these interventions as preventative medicines to enhance overall quality of life as individuals age. The latest milestone for Amplifier Therapeutics came with a significant $33.25M Series A investment on October 17, 2023, with participation from prominent investors including Future Ventures, RA Capital Management, and Cambrian Biopharma. This investment is indicative of the confidence placed in the company's mission and potential impact within the biotechnology and life sciences sectors.